Showing results (1891-1900 of 2,010) with videos related to

Sort By:
Pageof 201
Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
JAMA Network Open|January 16, 2019
Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical TrialApril W Armstrong, Cindy J Chambers, Emanual Maverakis, et al.
Epigenetics|May 26, 2023
Dietary and supplemental intake of vitamins C and E is associated with altered DNA methylation in an epigenome-wide association study meta-analysisAmena Keshawarz, Roby Joehanes, Jiantao Ma, et al.
Nature|May 23, 2007
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancersRichard S Maser, Bhudipa Choudhury, Peter J Campbell, et al.
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|September 4, 2020
[Analysis of treatment modalities and prognosis of patients with gallbladder cancer in China from 2010 to 2017]T Ren, Y S Li, Y J Geng, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
The Lancet. Oncology|January 25, 2022
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialMichael L Wang, Preetesh Jain, Shuangtao Zhao, et al.
Science (New York, N.Y.)|August 7, 2004
Basaltic rocks analyzed by the Spirit Rover in Gusev CraterH Y McSween, R E Arvidson, J F Bell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.
Pageof 201